SYNGAP1

基因产物:突触RAS-GTP酶激活蛋白1。

蛋白功能:主要定位于新皮质锥体神经元的树突小棘中,可抑制与NMDA受体介导的突触可塑性和AMPA受体膜内插入相关的信号通路。

相关疾病:智力发育迟滞(AD)[1];癫痫伴肌阵挛失张力发作(Doose syndrome)(AD)[2,3];肌阵挛失神癫痫(AD)[2]。

突变数据库:ClinVar数据库

相关研究:PubMed数据库(PMID: 32469098 (J Med Genet. 2020); PMID: 26989088 (J Med Genet. 2016); PMID: 19196676 (N Engl J Med. 2009)

用药提醒:有报道丙戊酸钠吡仑帕奈大麻二酚对部分该基因变异所致的癫痫患者有效[4-6]。

讨论版块点击进入SYNGAP1基因突变讨论版块

 

参考文献

  1. Hamdan, F. F., et al. (2009). "Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation." N Engl J Med 360(6): 599-605.
  2. Mignot, C., et al. (2016). "Genetic and neurodevelopmental spectrum of SYNGAP1-associated intellectual disability and epilepsy." J Med Genet 53(8): 511-522.
  3. Tang, S., et al. (2020). "Phenotypic and genetic spectrum of epilepsy with myoclonic atonic seizures." Epilepsia 61(5): 995-1007.
  4. 王晓乐,田亚男,陈晨,等.SYNGAP1基因变异相关常染色体显性智力障碍5型8例并文献复习[J].中国当代儿科杂志,2023,25(05):489-496.
  5. Perampanel as precision therapy in rare genetic epilepsies. Epilepsia. 2023 Apr;64(4):866-874.
  6. Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy. Epilepsia Open. 2020 Jul 1;5(3):496-500.